Aroa Biosurgery Limited

ASX:ARX Stock Report

Market Cap: AU$217.9m

Aroa Biosurgery Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Brian Ward

Chief executive officer

NZ$978.1k

Total compensation

CEO salary percentage58.21%
CEO tenure18.8yrs
CEO ownership9.6%
Management average tenure5.9yrs
Board average tenure6.6yrs

Recent management updates

Recent updates

Narrative Update • Jun 05

ARX: Positive Trial Results Will Underpin Future Earnings Power

Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.
Narrative Update • May 03

ARX: Positive Wound Trial Results Will Support Stronger Future Profitability

Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).
New Narrative • Apr 08

Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time

Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 24

Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier

Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, trauma, burns and reconstructive surgery. What are the underlying business or industry changes driving this perspective?
Analysis Article • Nov 28

Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...
User avatar
New Narrative • Apr 26

Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence

Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.
Analysis Article • Apr 07

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge

Unfortunately for some shareholders, the Aroa Biosurgery Limited ( ASX:ARX ) share price has dived 26% in the last...
Analysis Article • Mar 24

Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 15

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge

Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...
Analysis Article • Dec 04

Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%

Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...
Analysis Article • Nov 27

The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts

It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...
Analysis Article • Nov 13

We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 22

Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper

Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...
Analysis Article • Jun 12

Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

With a price-to-sales (or "P/S") ratio of 3.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...
Analysis Article • Mar 25

Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 30

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Aroa Biosurgery Limited ( ASX:ARX ) shareholders that were waiting for something to happen have been dealt a blow with...
Analysis Article • Nov 14

Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

With a price-to-sales (or "P/S") ratio of 4.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...
Analysis Article • Nov 02

Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Shareholders in Aroa Biosurgery Limited ( ASX:ARX ) may be thrilled to learn that the analysts have just delivered a...
Analysis Article • Oct 25

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

Does the October share price for Aroa Biosurgery Limited ( ASX:ARX ) reflect what it's really worth? Today, we will...
Analysis Article • May 13

We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 26

Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

Investors in Aroa Biosurgery Limited ( ASX:ARX ) had a good week, as its shares rose 6.2% to close at AU$1.20 following...
Analysis Article • Mar 22

An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Aroa Biosurgery...
Analysis Article • Feb 24

Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

A look at the shareholders of Aroa Biosurgery Limited ( ASX:ARX ) can tell us which group is most powerful...

CEO Compensation Analysis

How has Brian Ward's remuneration changed compared to Aroa Biosurgery's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

NZ$5m

Dec 31 2025n/an/a

NZ$1m

Sep 30 2025n/an/a

-NZ$2m

Jun 30 2025n/an/a

-NZ$3m

Mar 31 2025NZ$978kNZ$569k

-NZ$4m

Dec 31 2024n/an/a

-NZ$6m

Sep 30 2024n/an/a

-NZ$8m

Jun 30 2024n/an/a

-NZ$9m

Mar 31 2024NZ$1mNZ$583k

-NZ$11m

Dec 31 2023n/an/a

-NZ$9m

Sep 30 2023n/an/a

-NZ$8m

Jun 30 2023n/an/a

-NZ$4m

Mar 31 2023NZ$1mNZ$552k

-NZ$396k

Dec 31 2022n/an/a

-NZ$1m

Sep 30 2022n/an/a

-NZ$2m

Jun 30 2022n/an/a

-NZ$5m

Mar 31 2022NZ$1mNZ$542k

-NZ$8m

Dec 31 2021n/an/a

-NZ$10m

Sep 30 2021n/an/a

-NZ$11m

Jun 30 2021n/an/a

-NZ$15m

Mar 31 2021NZ$2mNZ$483k

-NZ$19m

Compensation vs Market: Brian's total compensation ($USD569.83K) is about average for companies of similar size in the Australian market ($USD619.87K).

Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.

CEO

Brian Ward

18.8yrs
Tenure
NZ$978,113
Compensation

Dr. Brian Ward, B.V.Sc, MBA(dist) has been Executive Director at Aroa Biosurgery Limited since September 21, 2007 and serves as its Managing Director and Chief Executive Officer. He has founded Aroa Biosur...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Ward
Founderno dataNZ$978.11k9.58%
A$ 20.9m
James Agnew
CFO & Joint Company Secretary6.3yrsNZ$627.01kno data
Rod Stanley
Chief Operating Officerno datano datano data
Yasmin Winchester
Chief of Technical Operationsno datano datano data
Barnaby May
Chief Scientific Officer4.5yrsno data0.95%
A$ 2.1m
Neetha Alex-Kumar
General Counselno datano datano data
Frazer Murray
Director of Global Marketing & Strategyno datano datano data
Tracy Weimar
Joint Company Secretary5.9yrsno datano data
Adam Young
Vice President of Medical Affairsno datano datano data
Sarah Tora
Media Executiveno datano datano data
5.9yrs
Average Tenure

Experienced Management: ARX's management team is seasoned and experienced (5.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Ward
Founder18.8yrsNZ$978.11k9.58%
A$ 20.9m
Paul Shearer
Non-Executive Directorless than a yearno data0.14%
A$ 315.0k
James McLean
Independent Non-Executive Chairperson14.8yrsNZ$173.88k0.82%
A$ 1.8m
John Diddams
Independent Non-Executive Director6.6yrsNZ$135.75k0.30%
A$ 650.5k
Philip McCaw
Non-Executive Director18.3yrsNZ$106.70k5.8%
A$ 12.6m
Catherine Mohr
Independent Non-Executive Director3.6yrsNZ$173.86k0.13%
A$ 274.9k
Darla Hutton
Independent Non-Executive Director2.3yrsNZ$174.59k0.041%
A$ 88.3k
6.6yrs
Average Tenure

Experienced Board: ARX's board of directors are considered experienced (6.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/17 09:36
End of Day Share Price 2026/06/17 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aroa Biosurgery Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Shane StoreyCanaccord Genuity
Scott PowerMorgans Financial Limited